Q. Bisantrene is not new. How can RAC monetise if it is out of patent?, page-77

Daniel, notwithstanding, all the to and fro and ifs and buts plus why and why nots, including some unsavory innuendo,
written is this thread has highlighted and answered the question for me as to why the professional and institutional investment capital has entered the market to bolster the share price on release of each positive new ASX announcement.
The answer as to how the suspected sceptism and risk aversion of the heavy hitter dollars can be dismissed or diminished seems of paramount importance to me. Is the roadshow presentation good enough to shift thinking?